The invention relates to an immobilized protein material comprising a protein that is immobilized on a glass material or organic polymer through affinity tag binding. The glass material may be a porous glass material such as (hybrid) controlled porosity glass. The invention also relates to the use of an immobilized enzyme material as a heterogeneous biocatalyst in chemical synthesis. The invention further relates to a method for the immobilization of affinity tagged proteins on a glass material or organic polymer, and to a method for the purification and isolation of affinity tagged proteins by the immobilization of such proteins on a glass material or organic polymer.

The invention relates to an immobilized protein material comprising a protein that is immobilized on a glass material or organic polymer through affinity tag binding. The glass material may be a porous glass material such as (hybrid) controlled porosity glass. The invention also relates to the use of an immobilized enzyme material as a heterogeneous biocatalyst in chemical synthesis. The invention further relates to a method for the immobilization of affinity tagged proteins on a glass material or organic polymer, and to a method for the purification and isolation of affinity tagged proteins by the immobilization of such proteins on a glass material or organic polymer.

Compositions and methods for the selective sequestration of metal ions are generally described.

The present invention provides methods for synthetic antibodies, methods for making synthetic antibodies, methods for identifying ligands, and related methods and reagents.

The present invention provides methods for synthetic antibodies, methods for making synthetic antibodies, methods for identifying ligands, and related methods and reagents.

Compounds comprising an isobaric region, an enrichment handle, and a thiol-reactive group are generally described. Methods of using the same (e.g., performing multiplexed quantitative analysis of the reactivity of one or more cysteine residues across multiple samples simultaneously) are also described.

Compounds comprising an isobaric region, an enrichment handle, and a thiol-reactive group are generally described. Methods of using the same (e.g., performing multiplexed quantitative analysis of the reactivity of one or more cysteine residues across multiple samples simultaneously) are also described.

A compound for the sequestration of undesirable antibodies (e.g. related to an autoimmune disease) in a patient. The compound includes an inert biopolymer scaffold and at least a first peptide n-mer of the general formula P(SP).sub.(n?1) and a second peptide n-mer of the general formula P(SP).sub.(n?1); wherein, independently for each occurrence, P is a peptide with a sequence length of 2-13 amino acids and S is a non-peptide spacer, wherein, independently for each of the peptide n-mers, n is an integer of at least 1, wherein each of the peptide n-mers is bound to the biopolymer scaffold. Also provided are pharmaceutical compositions including the compound, as well as a method of sequestering one or more antibodies present in an individual and a method of inhibiting an immune reaction to a treatment with an active agent.

A compound for the sequestration of undesirable antibodies (e.g. related to an autoimmune disease) in a patient. The compound includes an inert biopolymer scaffold and at least a first peptide n-mer of the general formula P(SP).sub.(n?1) and a second peptide n-mer of the general formula P(SP).sub.(n?1); wherein, independently for each occurrence, P is a peptide with a sequence length of 2-13 amino acids and S is a non-peptide spacer, wherein, independently for each of the peptide n-mers, n is an integer of at least 1, wherein each of the peptide n-mers is bound to the biopolymer scaffold. Also provided are pharmaceutical compositions including the compound, as well as a method of sequestering one or more antibodies present in an individual and a method of inhibiting an immune reaction to a treatment with an active agent.

The present invention relates to a targeting-type capsule for drug delivery systems. The present invention addresses the problem of providing a capsule for drug delivery systems by utilizing the reactivity of a thiol with an alkyl halide, wherein the capsule comprises a silole-containing carbosilane dendrimer and a labeling protein containing a target recognition site (e.g., green fluorescent protein), can include a biological polymer or another molecule therein, and can deliver the biological polymer or the like selectively into a target cell.